Light-activated cation channel and uses thereof

Patent metadata

Field	Value
Publication number	US-2016252524-A1
Application number	US-201615059159-A
Country	US
Kind code	A1
Filing date	Mar 2, 2016
Priority date	Jul 22, 2005
Publication date	Sep 1, 2016
Grant date	—

Abstract

The present invention provides compositions and methods for light-activated cation channel proteins and their uses within cell membranes and subcellular regions. The invention provides for proteins, nucleic acids, vectors and methods for genetically targeted expression of light-activated cation channels to specific cells or defined cell populations. In particular the invention provides millisecond-timescale temporal control of cation channels using moderate light intensities in cells, cell lines, transgenic animals, and humans. The invention provides for optically generating electrical spikes in nerve cells and other excitable cells useful for driving neuronal networks, drug screening, and therapy.

First claim

What is claimed is:

1 . A method of predicting potential ion channel modulating properties of a drug comprising:
(a) expressing a light-activated cation channel protein and an ion channel of interest in a cell; (b) exposing said cell to light and monitoring a first response in said cell; (c) exposing said cell to a candidate drug; (d) further exposing said cell to light and monitoring a second response in said cell; (e) determining an ion channel modulating property of said candidate drug based on a comparison of said first and second response.

2 . The method of claim 1 wherein the monitoring of the responses comprises optical imaging of changes in fluorescence in said cell.

3 . The method of claim 1 wherein the monitoring of the responses comprises monitoring a signal transduction pathway in said cell.

4 . The method of claim 3 wherein said monitoring of signal transduction is performed with an antibody, fluorescent small molecule, or a genetically encoded indicator.

5 . The method of claim 1 wherein said method is performed to evaluate for selective effects of said candidate drug on said ion channel of interest.

6 . The method of claim 1 wherein a differential effect of said candidate drug on channel splice variants, channel isoforms, channels expressed differentially in separate neuron types, channels expressed differentially in separate parts of the brain, channels expressed differentially in different organs, or channels that are expressed differentially over time is evaluated.

7 . The method of claim 1 wherein said ion channel of interest is a HERG channel.

8 . The method of claim 1 wherein the light-activated cation channel protein is ChR2, Chop2, ChR2-310, or Chop2-310.

9 . The method of claim 1 wherein the light-activated cation channel protein is coded by a sequence of SEQ ID No. 2 or SEQ ID No. 3.

Assignees

• Univ Leland Stanford Junior

Inventors

• Deisseroth Karl
• Boyden Edward S

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P5/50

  for increasing or potentiating the activity of insulin · CPC title

• A61P5/06

  of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH · CPC title

• A61P7/06

  Antianaemics · CPC title